Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sofia Dumois-Petersen"'
Autor:
Francisco Javier Perea-Díaz, María Teresa Magaña-Torres, Luis E. Figuera, Sofia Dumois-Petersen, Martha Patricia Gallegos-Arreola, John M. Ringman
Publikováno v:
American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 184:1023-1029
Mutations in three genes (APP, PSEN1, and PSEN2) are the main cause of the autosomal dominant early-onset Alzheimer's disease (AD-EOAD). In PSEN1, the A431E (c.1292C>A, rs63750083) mutation is suspected to have exerted a founder effect in the State o
Autor:
Angélica Zuno‐Reyes, Karina Pérez‐Rubio, Martín Alonso Flores‐González, Ricardo Jauregui Torres, Sofía Dumois‐Petersen, Luis E. Figuera, John M. Ringman, Esmeralda Matute
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 16, Iss 3, Pp n/a-n/a (2024)
Abstract INTRODUCTION We aimed to determine the effect of years of schooling (YoS) and age on the Mexican adaptation of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD‐MX) scores in preclinical carriers group (PCG) and non‐c
Externí odkaz:
https://doaj.org/article/47eb2ee19f614c938f98a53880703338
Autor:
Sofia, Dumois-Petersen, Martha P, Gallegos-Arreola, María T, Magaña-Torres, Francisco J, Perea-Díaz, John M, Ringman, Luis E, Figuera
Publikováno v:
American journal of medical genetics. Part C, Seminars in medical geneticsREFERENCES. 184(4)
Mutations in three genes (APP, PSEN1, and PSEN2) are the main cause of the autosomal dominant early-onset Alzheimer's disease (AD-EOAD). In PSEN1, the A431E (c.1292CA, rs63750083) mutation is suspected to have exerted a founder effect in the State of
Autor:
César A. Valdez-Gaxiola, Eric Jonathan Maciel-Cruz, Rubiceli Hernández-Peña, Sofía Dumois-Petersen, Frida Rosales-Leycegui, Martha Patricia Gallegos-Arreola, José Miguel Moreno-Ortiz, Luis E. Figuera
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 21, p 15687 (2023)
In Alzheimer’s disease (AD), the age of onset (AoO) exhibits considerable variability, spanning from 40 to 90 years. Specifically, individuals diagnosed with AD and exhibiting symptoms prior to the age of 65 are typically classified as early onset
Externí odkaz:
https://doaj.org/article/a45808d62b6f42fe9a810359ffaa9190